Back to Search
Start Over
New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
- Source :
-
The Journal of rheumatology. Supplement [J Rheumatol Suppl] 2015 Nov; Vol. 93, pp. 70-2. - Publication Year :
- 2015
-
Abstract
- The pathogenesis of psoriatic arthritis (PsA) is still under discussion but great advances have been made in the last 2 decades that confirm the central role of tumor necrosis factor-α (TNF-α) in its inflammatory milieu. New therapeutic approaches have been proposed, and new molecules with anti-TNF-α activity have been chemically altered to improve their pharmacological properties. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that has been shown clinically to be effective in the treatment of rheumatoid arthritis (RA), skin psoriasis, and PsA. This article summarizes available data on its clinical efficacy and safety profile in the treatment of patients with PsA.
- Subjects :
- Antirheumatic Agents adverse effects
Arthritis, Psoriatic diagnosis
Arthritis, Psoriatic immunology
Biological Products adverse effects
Certolizumab Pegol adverse effects
Humans
Treatment Outcome
Tumor Necrosis Factor-alpha immunology
Antirheumatic Agents therapeutic use
Arthritis, Psoriatic drug therapy
Biological Products therapeutic use
Certolizumab Pegol therapeutic use
Tumor Necrosis Factor-alpha antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 0380-0903
- Volume :
- 93
- Database :
- MEDLINE
- Journal :
- The Journal of rheumatology. Supplement
- Publication Type :
- Academic Journal
- Accession number :
- 26523062
- Full Text :
- https://doi.org/10.3899/jrheum.150641